Enanta Pharmaceuticals announces new data from Phase 2b interferon-free combination studies with protease inhibitor ABT-450 for hepatitis C treatment to be presented at EASL; results ontinue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types (ENTA) 20.43 : Co announced that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie (ABBV), as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress taking place in Amsterdam. Results from "Aviator," AbbVie's Phase 2b clinical trial of ABT-450 combined with two of AbbVie's proprietary investigational direct-acting antivirals (DAAs), for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. SVR rates of 96% to 99% after 12 weeks of treatment were achieved in patients new to treatment (na?ve) and 93% in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). In addition, similarly high SVR rates over 90% observed after 24 weeks of treatment in the Phase 2b trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination. The triple-DAA combination is currently being studied in Phase 3 clinical trials. 99% of treatment-na?ve patients achieved SVR12, 96% achieved SVR24 in this intent-to-treat analysis. 93% of prior null responders achieved SVR12 and SVR24. The single relapse with this regimen occurred at post-treatment week two.
